<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099539</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-02-13</org_study_id>
    <secondary_id>CA167925</secondary_id>
    <nct_id>NCT02099539</nct_id>
  </id_info>
  <brief_title>QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation&#xD;
      study of ALT-803 in patients with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, determine the Maximum Tolerated Dose&#xD;
      (MTD) or the Minimum Efficacious Dose (MED) and characterize the immunogenicity and&#xD;
      pharmacokinetic profile of ALT-803 in treated patients. The effect of ALT-803 on the&#xD;
      peripheral absolute lymphocyte counts and white blood cell counts, the number and phenotype&#xD;
      of peripheral blood T (total and subsets) and NK cells will be evaluated. The anti-tumor&#xD;
      responses of ALT-803 will also be assessed in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>24 months</time_frame>
    <description>For phase I &amp; II&#xD;
Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD or MED Determination, Phase II Dose Level Designation</measure>
    <time_frame>9 months</time_frame>
    <description>For phase I only&#xD;
Determine the maximum tolerated dose (MTD) level or minimum efficacious dose (MED) and designate the dose level for phase II.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>24 months</time_frame>
    <description>For phase I and II&#xD;
Number of participants with an objective response, which includes, a complete response, a partial response or a stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Cell Counts</measure>
    <time_frame>24 months</time_frame>
    <description>For phase Ib and II&#xD;
Evaluation of the effect of ALT-803 on the peripheral ALC and WBC counts, the number and phenotype of peripheral blood T (total and subsets) and NK cells in treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24 months</time_frame>
    <description>For phase I and II&#xD;
Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-803.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>24 months</time_frame>
    <description>For phase I and II&#xD;
Measures the serum levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma, MCP-1 and TNF-alpha in treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>24 months</time_frame>
    <description>For Phase I and II&#xD;
Measures the anti-ALT-803 neutralizing effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>All enrolled patients will be assessed every 3 months during year 1 and then every 6 months during years 2 and 3 from the start of study treatment to determine their overall survival, progression-free survival and duration of response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ALT-803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles</description>
    <arm_group_label>ALT-803</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ENTRY CRITERIA:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at&#xD;
             least two different previous regimens.&#xD;
&#xD;
               -  Refractory disease is defined as progressive disease while on therapy or&#xD;
                  progression within 60 days of therapy.&#xD;
&#xD;
               -  Progressive disease is defined by a 25% increase from the lowest response value&#xD;
                  in specified tests.&#xD;
&#xD;
          -  Measurable disease as defined by at least one of the following:&#xD;
&#xD;
               -  Serum M-protein ≥ 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)&#xD;
&#xD;
               -  Urine M-protein ≥ 200mg/24hours&#xD;
&#xD;
               -  Serum free light chains ≥ 10 mg/dL and abnormal kappa/lambda ratio&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
          -  No anti-myeloma treatments within 14 days before the start of study treatment.&#xD;
&#xD;
          -  Must have recovered from side effects of prior treatments.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance Status&#xD;
&#xD;
        • ECOG 0, 1, or 2&#xD;
&#xD;
        Bone Marrow Reserve&#xD;
&#xD;
          -  Absolute neutrophil count (AGC/ANC) ≥ 1000/uL&#xD;
&#xD;
          -  Platelets ≥ 30,000/uL&#xD;
&#xD;
          -  Hemoglobin ≥ 8g/dL&#xD;
&#xD;
          -  Absolute lymphocytes ≥ 800/uL&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/uL&#xD;
&#xD;
        Renal Function&#xD;
&#xD;
        • Glomerular Filtration Rate (GFR) &gt; 40mL/min or Serum creatinine ≤ 1.5 X ULN&#xD;
&#xD;
        Hepatic Function&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0 X ULN&#xD;
&#xD;
          -  AST, ALT, ALP ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver metastases exist)&#xD;
&#xD;
          -  No positive Hep C serology or active Hep B infection&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure &lt; 6 months&#xD;
&#xD;
          -  No unstable angina pectoris &lt; 6 months&#xD;
&#xD;
          -  No myocardial infarction &lt; 6 months&#xD;
&#xD;
          -  No history of ventricular arrhythmias&#xD;
&#xD;
          -  No history of supraventricular arrhythmias&#xD;
&#xD;
          -  No NYHA Class &gt; II CHF&#xD;
&#xD;
          -  No marked baseline prolongation of QT/QTc interval&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
        • Normal clinical assessment of pulmonary function&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Negative serum pregnancy test if female and of childbearing potential&#xD;
&#xD;
          -  Women who are not pregnant or nursing&#xD;
&#xD;
          -  Subjects, both females and males, with reproductive potential must agree to use&#xD;
             effective contraceptive measures for the duration of the study&#xD;
&#xD;
          -  No known autoimmune disease other than corrected hypothyroidism&#xD;
&#xD;
          -  No known prior organ allograft or allogeneic transplantation&#xD;
&#xD;
          -  Not HIV positive&#xD;
&#xD;
          -  No history or evidence of uncontrollable CNS disease&#xD;
&#xD;
          -  No psychiatric illness/social situation&#xD;
&#xD;
          -  No other illness that in the opinion of the investigator would exclude the subject&#xD;
             from participating in the study&#xD;
&#xD;
          -  Must provide informed consent and HIPPA authorization and agree to comply with all&#xD;
             protocol-specified procedures and follow-up evaluations&#xD;
&#xD;
          -  No active systemic infection requiring parenteral antibiotic therapy&#xD;
&#xD;
          -  No on-going chronic systemic corticosteroid (&gt;10 mg daily prednisone equivalent) use&#xD;
             or other immunosuppressive therapy (a history of mild asthma not requiring therapy is&#xD;
             eligible). Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg&#xD;
             daily prednisone equivalent, are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hing C Wong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Altor BioScience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>absolute lymphocyte count</keyword>
  <keyword>antitumor</keyword>
  <keyword>cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immunochemotherapy</keyword>
  <keyword>interleukin-15</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>NK cell</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>T cell</keyword>
  <keyword>white blood cell count</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

